CLINICAL TRIALS PROFILE FOR FLUOXETINE HYDROCHLORIDE; OLANZAPINE
✉ Email this page to a colleague
All Clinical Trials for Fluoxetine Hydrochloride; Olanzapine
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00000373 ↗ | Treatment of Obsessive-Compulsive Disorder | Completed | National Institute of Mental Health (NIMH) | Phase 4 | 1992-09-01 | The purpose of this study is to find the best treatment for Tourette's Syndrome (TS)-spectrum obsessive-compulsive disorder (OCD), which includes symptoms of TS, e.g., repeated and involuntary body movements (tics). There are 2 parts to this study: In Part 1, patients are placed into 1 of 2 groups based on type of OCD, determined by medical history and family member interviews. In Part 2, patients are treated with fluvoxamine (FVX) for 8 weeks. If patients do not respond to FVX alone, either haloperidol or an inactive placebo will be added to the FVX regimen; patients will take this drug combination for 4 weeks. Patients will be monitored throughout the trial. |
| NCT00000373 ↗ | Treatment of Obsessive-Compulsive Disorder | Completed | University of Florida | Phase 4 | 1992-09-01 | The purpose of this study is to find the best treatment for Tourette's Syndrome (TS)-spectrum obsessive-compulsive disorder (OCD), which includes symptoms of TS, e.g., repeated and involuntary body movements (tics). There are 2 parts to this study: In Part 1, patients are placed into 1 of 2 groups based on type of OCD, determined by medical history and family member interviews. In Part 2, patients are treated with fluvoxamine (FVX) for 8 weeks. If patients do not respond to FVX alone, either haloperidol or an inactive placebo will be added to the FVX regimen; patients will take this drug combination for 4 weeks. Patients will be monitored throughout the trial. |
| NCT00035321 ↗ | The Study of Olanzapine Plus Fluoxetine in Combination for Treatment of Treatment Resistant Depression | Completed | Eli Lilly and Company | Phase 3 | 2002-04-01 | The purposes of this study are to determine: - Whether olanzapine plus fluoxetine in combination will help patients with treatment-resistant major depression. - The safety of olanzapine plus fluoxetine in combination, plus and any side effects that might be associated with the combination. - The effectiveness of olanzapine plus fluoxetine compared to olanzapine and fluoxetine alone. |
| NCT00188942 ↗ | A Neuroimaging Investigation of Brain Activity in Major Depressive Disorder and Bipolar Disorder | Completed | Eli Lilly and Company | Phase 4 | 2005-02-01 | This study employs functional magnetic resonance imaging to compare brain activation patterns during a depressive episode in patients diagnosed with bipolar disorder, major depressive disorder, and a group of healthy control subjects. Depressed patients will be treated with a combination of fluoxetine and olanzapine and undergo MRI scans before, during, and after pharmacotherapy. |
| NCT00188942 ↗ | A Neuroimaging Investigation of Brain Activity in Major Depressive Disorder and Bipolar Disorder | Completed | University Health Network, Toronto | Phase 4 | 2005-02-01 | This study employs functional magnetic resonance imaging to compare brain activation patterns during a depressive episode in patients diagnosed with bipolar disorder, major depressive disorder, and a group of healthy control subjects. Depressed patients will be treated with a combination of fluoxetine and olanzapine and undergo MRI scans before, during, and after pharmacotherapy. |
| NCT00191399 ↗ | Bipolar Depression Study: Bipolar Depression Assessment Study on Treatment Response | Completed | Eli Lilly and Company | Phase 4 | 2004-05-01 | The primary objective of this study is to assess the efficacy of olanzapine and fluoxetine combined on all the visits as compared with the baseline visit in patients with bipolar disorder, measured by the total score of the Montgomery-Asberg Depression Rating Scale (MADRS). |
| NCT00485771 ↗ | Olanzapine/Fluoxetine Combination Versus Comparator in the Treatment of Bipolar I Depression | Completed | Eli Lilly and Company | Phase 4 | 2003-11-01 | The purpose of this study is to assess olanzapine/fluoxetine combination and lamotrigine comparative efficacy, safety and tolerability in acute and longer term treatment of bipolar depression. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Fluoxetine Hydrochloride; Olanzapine
Condition Name
Clinical Trial Locations for Fluoxetine Hydrochloride; Olanzapine
Trials by Country
Clinical Trial Progress for Fluoxetine Hydrochloride; Olanzapine
Clinical Trial Phase
Clinical Trial Sponsors for Fluoxetine Hydrochloride; Olanzapine
Sponsor Name
